ThinkEquity initiated coverage of Regentis Biomaterials with a Buy rating and $10 price target. Regentis is a single-asset medtech company advancing GelrinC for focal knee cartilage defects, the analyst tells investors in a research note. The firm says "de-risking is underway."
